Whether management can run this without the founder from regulatory-approval

Situation

Management can run this sits with IP diligence counsel's financial counterpart because a founder who will not sign a non-compete hit a strategic buyer looking at a carve-out from a conglomerate. Evidence is regulatory-approval critical-path calendar; write the M&A Due Diligence Earnings and Revenue Quality option that extract can carry.

Decision

IP diligence counsel's financial counterpart in a strategic buyer looking at a carve-out from a conglomerate must choose Proceed / Reprice / Walk / Hold using regulatory-approval critical-path calendar after a founder who will not sign a non-compete.

Hypotheses to test

• Regulatory-approval critical-path calendar reads as Proceed once a founder who will not sign a non-compete is lined up to the same M&A Due Diligence population.
• Regulatory-approval critical-path calendar is closer to Reprice after a founder who will not sign a non-compete; Proceed would over-claim this Earnings and Revenue Quality extract.
• Walk is still live in regulatory-approval critical-path calendar for IP diligence counsel's financial counterpart in a strategic buyer looking at a carve-out from a conglomerate.
• Regulatory-approval critical-path calendar is missing the fact IP diligence counsel's financial counterpart needs after a founder who will not sign a non-compete; stop this M&A Due Diligence close.

Analysis required

• Name the document IP diligence counsel's financial counterpart still needs before signing.
• Test whether a founder who will not sign a non-compete is a diligence gap, a price chip, or a walk-away.
• Separate a one-off add-back from a recurring earnings issue in regulatory-approval critical-path calendar.
• For this M&A Due Diligence Earnings and Revenue Quality file, read regulatory-approval critical-path calendar against a founder who will not sign a non-compete and write the one fact that would move management can run this for IP diligence counsel's financial counterpart.

Recommendation

Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Earnings and Revenue Quality packet (regulatory-approval critical-path calendar after a founder who will not sign a non-compete). Lead with the M&A Due Diligence option regulatory-approval critical-path calendar can support after a founder who will not sign a non-compete, then the two facts that force it, then the Monday action for IP diligence counsel's financial counterpart in a strategic buyer looking at a carve-out from a conglomerate.